At Phytex, we’re committed to combining science and nature to better people’s lives. For over 40 years, we've specialised in the contract manufacture of APIs from natural resources for the global pharmaceutical industry and research communities. From R&D to commercial production, we focus on the discovery, sustainable extraction and isolation of niche Australian native botanicals to transform them into life-changing pharmaceuticals. We’ve developed extraction, isolation and analytical technology of alkaloids and glycosides for products such as Scopolamine (Hyoscine) - Hydrobromide, Methylbromide, Base, Hyoscyamine Atropine and Aesculin (Esculin), Indolizidines, such as Castanospermine and Swainsonine. Plus, steroidal compounds from botanical sources like Ecdysteroids(Ecysone and Ponasterone). As champion innovators, our recent focus toward medicinal cannabis is an example of our ability to identify trends and transform them into products with our clients. Phytex has recently initiated R&D works that are focussed toward the application of proprietary in-house extraction and purification methods in the production of high purity CBD Isolates and purified cannabinoids for pharmaceutical API use. Looking at the past four decades, our long-standing product registrations, and the fact we’ve had zero product recalls, are a standout from our competitors. Our history is the solid foundation on which we move forward with innovation and collaboration top of mind. We continue to scale and commercialise ingredients without compromising on quality or our commitment to sustainability. As an Australian owned and operated company, the Made in Australia logo guides our work ethic as we maintain its reputation for superior product performance worldwide. Our manufacturing is centred on strict accordance with cGMP and ICH Quality Guidelines - ICHQ7 – and 21CFR part 210 and 211. Phytex holds current regulatory licensing with the TGA, US FDA & EDQM and for all commercial products.